GlassScriptPhysician profile
Jasmine Teamer
NPI 1760976153
$1,250.48
in general payments reported to CMS, 2019-2025
18 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 87% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $229 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.49 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $203.63 | 2024-2025 | Pifeltro, Delstrigo, Capvaxive |
| Astellas Pharma US INC | $145.51 | 2025 | Cresemba |
| Paratek Pharmaceuticals, INC. | $120.17 | 2024-2025 | Nuzyra |
| Gilead Sciences, INC. | $107.62 | 2024-2025 | Biktarvy, Veklury |
| Takeda Pharmaceuticals U.S.A., INC. | $87.81 | 2024-2025 | Cuvitru |
| Melinta Therapeutics, LLC | $72.18 | 2025 | Orbactiv, Kimyrsa, Rezzayo |
| Napo Pharmaceuticals INC | $64.57 | 2025 | Mytesi |
| La Jolla Pharmaceutical Company | $58.50 | 2024-2025 | Xerava, Zevtera |
| Cumberland Pharmaceuticals, INC. | $54.13 | 2025 | Vibativ |
| Abbvie INC. | $53.79 | 2025 | |
| Viiv Healthcare Company | $53.70 | 2025 | Dovato, Cabenuva |
| Insmed, INC. | $47.51 | 2025 | Arikayce |
| Pfizer INC. | $40.23 | 2025 | |
| Theratechnologies INC. | $37.53 | 2025 | Egrifta, Trogarzo |
| Otsuka America Pharmaceutical, INC. | $33.71 | 2024 | Nuedexta |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $25.71 | 2025 | |
| Janssen Biotech, INC. | $23.13 | 2024 | Erleada, Akeega |
| Shionogi INC | $21.05 | 2025 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Teamer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.